Skip to main content
Evidence Snapshot

Streptococcus

CHEMBL612313 ORGANISM Streptococcus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:11Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL612313
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Streptococcus as ChEMBL target CHEMBL612313. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Streptococcus
ORGANISM · Streptococcus
As of 2026-09-14
ChEMBL target ID
CHEMBL612313
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Streptococcus matters

As of 2026-09-14

Streptococcus is reviewed as Streptococcus; the current evidence base includes 32 approved drugs, 3590 compounds, and 122 assays, with lead potency reaching pChEMBL 7.2.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 32 approved drugs, 3590 compounds, and 122 assays for this target. The dominant activity type is EC50. CHEMBL586135 is the current potency anchor at pChEMBL 7.2.

Use CHEMBL586135 as the tractability anchor when discussing potency (pChEMBL 7.2).

Activity source · ChEMBL 36 via Core Engine
32 approved pChEMBL 7.2
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Streptococcus matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

3590
Total Compounds
122
Total Assays
32
Approved Drugs
IC50: 2.0, EC50: 3339.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL586135
 7.2 EC50 —
No preferred name
CHEMBL529
 7.2 EC50 Approved
No preferred name
CHEMBL1467058
 7.2 EC50 —
No preferred name
CHEMBL581257
 7.1 EC50 —
No preferred name
CHEMBL12131
 7.0 EC50 Clinical

Approved Drugs

Structure Compound First Approval
LINEZOLID
CHEMBL126
 2000
MOXIFLOXACIN HYDROCHLORIDE
CHEMBL1200735
 1999
LEVOFLOXACIN
CHEMBL5315124
 1996
DIRITHROMYCIN
CHEMBL1237072
 1995
CEFPODOXIME PROXETIL
CHEMBL1201016
 1992
AZITHROMYCIN
CHEMBL529
 1991
METHACYCLINE HYDROCHLORIDE
CHEMBL2146123
 1982
PIPERACILLIN SODIUM
CHEMBL1200820
 1981
CHLORTETRACYCLINE HYDROCHLORIDE
CHEMBL2146063
 1950
HEXACHLOROPHENE
CHEMBL496
 1949
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:11Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL612313